Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 5/20 | 0.48 |
| ▸ | DYRK3 | O43781 | 4/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.48 |
| ▸ | CDK9 | P50750 | 4/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.48 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.48 |
| ▸ | DYRK2 | Q92630 | 4/20 | 0.48 |
| ▸ | DYRK1B | Q9Y463 | 4/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.46 |
| ▸ | CDK2 | P24941 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 2/20 | 0.40 |
| ▸ | CLK1 | P49759 | 4/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.39 |
| ▸ | CHRNA10 | Q9GZZ6 | 2/20 | 0.39 |
| ▸ | CHRNA9 | Q9UGM1 | 2/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19781167 | 0.96 | DYRK3 (0.51) | DYRK1ADYRK3CCNT1CDK9CDK5 | |
| SCHEMBL19781131 | 0.92 | CLK1 (0.41) | DYRK1ADYRK3CCNT1CDK9CDK5 | |
| SCHEMBL19781579 | 0.85 | FYN (0.47) | DYRK1ADYRK3CCNT1CDK9CDK5 | |
| SCHEMBL19781272 | 0.85 | DYRK3 (0.43) | DYRK1ADYRK3CCNT1CDK9CDK5 | |
| SCHEMBL19781133 | 0.85 | RIPK2 (0.48) | DYRK1ADYRK3CCNT1CDK9CDK5 | |
| SCHEMBL19781539 | 0.83 | CLK1 (0.47) | DYRK1AKCNH2FYNCLK1PIK3CA | |
| SCHEMBL19781262 | 0.82 | CHRNB4 (0.39) | DYRK1ADYRK3CCNT1CDK9CDK5 | |
| SCHEMBL19781806 | 0.79 | GRK5 (0.48) | DYRK1AKCNH2FYNCLK1LRRK2 | |
| SCHEMBL19781810 | 0.78 | KCNH2 (0.43) | DYRK1AKCNH2FYNCLK1LRRK2 | |
| SCHEMBL24460223 | 0.77 | BCL2 (0.44) | DYRK1AKCNH2FYNCLK1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-11352328-B2 | Heterocyclic compounds for the treatment of arenavirus | ARISAN THERAPEUTICS INC. (US) | 2022-06-07 | — | — | US | disclosed |
| WO-2022108849-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20190308938-A1 | Heterocyclic Compounds for the Treatment of Arenavirus | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-10-10 | — | — | US | disclosed |
| WO-2018013430-A2 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | C3AR1, C9, C1R | DYRK1A 4426/4885DYRK3 4183/4885CCNT1 17/4885 |
| US-11352328-B2 | Heterocyclic compounds for the treatment of arenavirus | C9, C1R, C1S | DYRK1A 4561/4885DYRK3 4459/4885CCNT1 423/4885 |
| US-20190308938-A1 | Heterocyclic Compounds for the Treatment of Arenavirus | C9, C1R, C1S | DYRK1A 4561/4885DYRK3 4459/4885CCNT1 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.